K
Kari Alitalo
Researcher at University of Helsinki
Publications - 844
Citations - 122462
Kari Alitalo is an academic researcher from University of Helsinki. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor C. The author has an hindex of 174, co-authored 817 publications receiving 114231 citations. Previous affiliations of Kari Alitalo include Mount Sinai Hospital, Toronto & Cornell University.
Papers
More filters
Journal ArticleDOI
PROX1 is involved in progression of rectal neuroendocrine tumors, NETs
Juha Jernman,Pauliina Kallio,Jaana Hagström,Matti Välimäki,Hannu Haapasalo,Kari Alitalo,Johanna Arola,Caj Haglund,Caj Haglund +8 more
TL;DR: Results indicate that immunohistochemical detection of PROX1 correlates with a more malignant phenotype in rectal NETs and may be involved in progression of rectalNETs as a part of the Wnt pathway.
Book ChapterDOI
The TIE Receptor Family
TL;DR: Preclinical results demonstrate that genetic TIE1 deletion in mice inhibits the vascularization and growth of tumor isografts and protects from atherosclerosis, with little effect on normal vascular homeostasis in adult mice.
Journal ArticleDOI
Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer
Yoshitaka Sekido,Toshitada Takahashi,Tomi P. Mäkelä,Y Obata,Ryuzo Ueda,Toyoaki Hida,Kenji Hibi,Kaoru Shimokata,Kari Alitalo +8 more
TL;DR: Long-range analysis using pulsed-field gel electrophoresis revealed that the amplified L-myc locus is involved in highly complex intrachromosomal rearrangements with jal and/or rlf, and suggests that the simultaneous presence of rearrangement both in rlf intron 1 and in regions immediately upstream of L- myc may be necessary for the expression of rlf-L-myC chimeric transcripts.
Journal Article
Expression of a rlf/L-myc minigene inhibits differentiation of embryonic stem cells and embroid body formation.
TL;DR: expression of a rlf/L-myc fusion may be of critical importance in tumorigenesis by blocking differentiation and thereby allowing continued proliferation of cells and the acquisition of further mutations leading to a fully malignant tumor.
Patent
Modified VEGF-A with improved angiogenic properties
Kari Alitalo,Tuomas Tammela,Salla Keskitalo,Katri Pajusola,Markku M. Jeltsch,Seppo Ylä-Herttuala,Terhi Karpanen,Ulf Eriksson,Marko Uutela +8 more
TL;DR: In this article, the authors present methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand, and the chimeric molecules of the present invention retain VEG FR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.